# FID-007

Source: https://onco.cc/drugs/fid-007/  
OnCo record `fid-007` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

FID-007 is an experimental nanoencapsulated paclitaxel, a taxane chemotherapy from Fulgent Genetics, in phase 2 trials for head and neck squamous cell carcinoma, pancreatic cancer and ampullary cancer.

## Summary

FID-007 (FID007, Paclitaxel in polyethyloxazoline polymer) is a nanoencapsulated paclitaxel, a taxane chemotherapy (polyethyloxazoline polymer) from Fulgent Genetics, with University of Southern California as partner. Paclitaxel encapsulated in a polyethyloxazoline (PEOX) polymer, designed to promote tumour penetration and retention. Its furthest stage is phase 2, for head and neck squamous cell carcinoma, pancreatic cancer and ampullary cancer. ClinicalTrials.gov registers it in 3 studies linked below. Randomised phase 2 with cetuximab in R/M HNSCC (NCT06332092) fully enrolled, active not recruiting. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-11-03
- Also known as: FID007; Paclitaxel in polyethyloxazoline polymer
- Tags: pipeline; ctgov-ingest
- Code: FID-007
- Modality: Nanoencapsulated paclitaxel, a taxane chemotherapy (polyethyloxazoline polymer)
- Mechanism: Paclitaxel encapsulated in a polyethyloxazoline (PEOX) polymer, designed to promote tumour penetration and retention.

## Sources

- Fulgent Genetics: sec.gov: https://www.sec.gov/Archives/edgar/data/1674930/000119312526326119/flgt-ex99_2.htm
- Fulgent Genetics: sec.gov: https://www.sec.gov/Archives/edgar/data/1674930/000119312526326119/flgt-ex99_2.htm
- Fulgent Genetics: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT03537690
- ClinicalTrials.gov: trials of FID-007: https://clinicaltrials.gov/search?intr=FID-007

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- companies: [Fulgent Genetics](https://onco.cc/companies/fulgent-genetics/)
- trials: [FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma](https://onco.cc/trials/nct06332092/), [FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer](https://onco.cc/trials/nct06338657/), [FID-007 in Treating Participants With Advanced Solid Tumors](https://onco.cc/trials/nct03537690/)

---
JSON: https://onco.cc/api/v1/entities/fid-007.json